

- Foley K, Gelband H, eds. *Institute of Medicine. National Cancer Policy Board. Improving Palliative Care for Cancer*. Washington, DC: National Academies Press; 2001.
- Foley KM. Advances in cancer pain. *Arch Neurol* 1999;56:413-417.
- National Institute of Health. Improving end-of-life care. *NIH Consens State Sci Statements* 2004;21:23.
- Foley KM. Clinical crossroads: a 44-year old woman with severe pain at the end of life. *JAMA* 1999;281:1937-1945.
- Moryl N, Coyle N, Foley KM. Managing an acute pain crisis in a patient with advanced cancer: "this is as much of a crisis as a code". *JAMA* 2008;299:1457-1467.
- Stjernsward J, Foley KM, Ferris FD. The public health strategy for palliative care. *J Pain Symptom Manage* 2007;33:486-493.
- World Health Organization. *Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee*. Geneva: World Health Organization; 1990.
- World Health Organization. *Cancer Pain Relief*. 2nd ed. Geneva: WHO; 1996.
- Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care into Standard Oncology Care. *J Clin Oncol* 2012;30:880-887.
- Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *New Engl J Med* 2010;363:733-742.
- Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. *Arch Intern Med* 2005;165:1574-1580.
- Jost L, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. *Ann Oncol* 2010;21:v257-v260.
- Raphael J, Ahmedzai S, Hester J, et al. Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. *Pain Med* 2010;11:742-764.
- Sanft TB, Von Roenn JH. Palliative care across the continuum of cancer care. *J Natl Compr Canc Netw* 2009;7:481-487.
- Swam RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. *J Natl Compr Canc Netw* 2013;11:992-1022.
- Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. *Ann Oncol* 2012;23:vii139-vii154.
- Foley KM, Wagner JL, Jornason DE, et al. Pain control for people with cancer and AIDS. In: Jamison DT, Breman JG, Measham AR, et al., eds. *Disease Control Priorities in Developing Countries*. 2nd ed. New York: Oxford University Press; 2006: 981.
- Foley KM. How well is cancer pain treated? *Palliat Med* 2011;25:398-401.
- Foley KM. Acute and chronic cancer pain syndromes. In: Doyle D, Hanks G, Cherny N, Calman K, eds. *Oxford Textbook of Palliative Medicine*. 3rd ed. New York: Oxford University Press; 2004: 298.
- Gonzales GR, Elliott KJ, Portenoy RK, et al. The impact of a comprehensive evaluation in the management of cancer pain. *Pain* 1991;47:141-144.
- Moulin D, Foley K. A review of a hospital-based pain service. In: Foley K, Bonica J, Ventafridda V, eds. *Advances in Pain Research and Therapy*. New York: Raven Press; 1990: 413.
- Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. *Oncol Nurs Forum* 2006;33:931-936.
- Gulluoglu BM, Cingi A, Cakir T, et al. Factors related to post-treatment chronic pain in breast cancer survivors: the interference of pain with life functions. *Int J Fertil Womens Med* 2006;51:75-82.
- Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. *JAMA* 1998;279:1877-1882.
- Cherny NI, Portenoy RK. Cancer pain: principles of assessment and syndromes. In: Wall PK, Melzack R, eds. *Textbook of Pain*. London: Churchill Livingstone; 1994: 787.
- Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med* 1994;330:592-596.
- Ellis JA, McCarthy P, Hershon L, et al. Pain practices: a cross-Canada survey of pediatric oncology centers. *J Pediatr Oncol Nurs* 2003;20:26-35.
- Portenoy RK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. *Cancer* 1994;74: 907-915.
- Portenoy RK, Miransky J, Thaler HT, et al. Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. *Cancer* 1992;70:1616-1624.
- Schuit KW, Sleijfer DT, Meijer WJ, et al. Symptoms and functional status of patients with disseminated cancer visiting outpatient departments. *J Pain Symptom Manage* 1998;16:290-297.
- The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). *JAMA* 1995;274:1591-1598.
- Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. *Ann Neurol* 1992;31:268-273.
- Coyle N, Adelhardt J, Foley KM, et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. *J Pain Symptom Manage* 1990;5:83-93.
- Chochinov H, Breitbart W, eds. *Handbook of Psychiatry in Palliative Medicine*. New York: Oxford University Press; 2009.
- Passik S, Portenoy R. Substance abuse issues in palliative care. In: Berger A, et al, eds. *Principles and Practices of Supportive Oncology*. Philadelphia: Lippincott-Raven Publishers; 1998.
- Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. *Pain* 1979;6:249.
- Cervero F, Laird JM. Visceral pain. *Lancet* 1999;353:2145-2148.
- Elliott K, Foley KM. Neurologic pain syndromes in patients with cancer. *Crit Care Clin* 1990;6:393-420.
- Clohisy DR, Mantyh PW. Bone cancer pain. *Cancer* 2003;97:866-873.
- Lindsay TH, Jonas BM, Sevcik MA, et al. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. *Pain* 2005;119:233-246.
- Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. *Exp Neurol* 2007;203:42-54.
- Hagen NA, Fisher K, Victorino C, et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. *J Palliat Med* 2007;10:47-55.
- Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. *J Pain Symptom Manage* 1999;17:391-401.
- Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. *Pain* 1990;41:273-281.
- Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. *Pain* 1999;79:303-312.
- Berry P, Dahl J. The new JCAHO pain schedule: implications for pain management nurses. *Pain Management News* 2000;1:3-12.
- Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain* 1983;17:197-210.
- Graham C, Bond SS, Gerkovich MM, et al. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. *Pain* 1980;8:377-387.
- Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. *J Clin Oncol* 2012;30:4249-4255.
- Miriovsky BJ, Abernethy AP. Use of patient-reported outcomes in registries. In: Glicklich RE, Dreyer NA, eds. *Registries for Evaluating Patient Outcomes*. 3rd ed. Bethesda, MD: Agency for Healthcare Research and Quality; 2012: 80-106.
- Miriovsky BJ, Abernethy AP. Measurement of quality of life outcomes. In: Berger AM, Shuster JL, Von Roenn JH, eds. *Principles and Practice of Palliative Oncology and Supportive Oncology*. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2013.
- Chang VT, Hwang SS, Feuerman M, et al. The memorial symptom assessment scale short form (MSAS-SF). *Cancer* 2000;89:1162-1171.
- Hwang SS, Chang VT, Fairclough DL, et al. Development of a cancer pain prognostic scale. *J Pain Symptom Manage* 2002;24:366-378.
- Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365-376.
- Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. *Cancer* 2000;88:2164-2171.
- Foley KM. The treatment of cancer pain. *N Engl J Med* 1985;313:84-95.
- Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. *JAMA* 2001;285:2898-2905.
- Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a definition and taxonomy. *J Palliat Care* 1994;10:57-70.
- Cherny NI, Coyle N, Foley KM. Guidelines in the care of the dying cancer patient. *Hematol Oncol Clin North Am* 1996;10:261-286.
- Foley KM. The relationship of pain and symptom management to patient requests for physician-assisted suicide. *J Pain Symptom Manage* 1991;6:289-297.
- Cassel EJ. The nature of suffering and the goals of medicine. *N Engl J Med* 1982;306:639-645.
- Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. *Am J Psychiatry* 1995;152:1185-1191.
- Cherny NI, Foley KM. Brachial plexopathy in patients with breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne D, eds. *Diseases of the Breast*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1996: 796.
- Ventafridda V, Caraceni A, Gamba A. Field-testing of the WHO Guidelines for Cancer Pain Relief: summary report of demonstration projects. In: Foley K, Bonica J, Ventafridda V, Callaway M, eds. *Second International Congress on Cancer Pain. Advances in Pain Research and Therapy*. Vol 16. New York: Raven Press; 1990: 451.

65. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain* 1995;63:65–76.
66. Du Pen SL, Du Pen AR, Polissar N, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. *J Clin Oncol* 1999;17:361–370.
67. Fallon M, Hanks G, Cheryn N. Principles of control of cancer pain. *BMJ* 2006;332:1022–1024.
68. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. *J Clin Oncol* 1994;12:2756–2765.
69. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. [see comment] [summary for patients in Can Fam Physician. 2002 Sep;48:1449-51; PMID: 12371303]. *JAMA* 2001;286:954–959.
70. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 2011;342:c7086.
71. Ventafridda V, De Conno F, Panerai AE, et al. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, inpatient study comparing nine drugs. *J Int Med Res* 1990;18:21–29.
72. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastrointestinal ulcers. [update of Cochrane Database Syst Rev. 2000;(4):CD002296; PMID: 11034748]. *Cochrane Database Syst Rev* 2002;CD002296.
73. Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. *Am J Med* 2006;119:448.e427–e436.
74. Langman MJ. Treating ulcers in patients receiving anti-arthritis drugs. *Q J Med* 1989;73:1089–1091.
75. McNicol E, Strassels SA, Goudas L, et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. *Cochrane Database Syst Rev* 2005;CD005180.
76. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. *Cancer* 1996;78:852–857.
77. Cheryn N, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. *Cancer* 1995;76:1283–1293.
78. Foley KM. Controversies in cancer pain. Medical perspectives. *Cancer* 1989;63:2257–2265.
79. Foley KM. Changing concepts of tolerance to opioids. What the cancer patient has taught us. In: Chapman C, Foley K, eds. *Current and Emerging Issues in Cancer Pain: Research and Practice*. New York: Raven Press; 1993: 331.
80. Foley KM. Pain relief into practice: rhetoric without reform. *J Clin Oncol* 1995;13:2149–2151.
81. Foley KM. Competent care for the dying instead of physician-assisted suicide. [see comment]. *N Engl J Med* 1997;336:54–58.
82. Foley KM. Opioids and chronic neuropathic pain. [see comment][comment]. *N Engl J Med* 2003;348:1279–1281.
83. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. *JAMA* 1995;274:1870–1873.
84. Joranson D, Ryan KM, Maurer MA. Opioid policy, availability and access in developing and non-industrialized countries. In: Fishman S, Ballantyne J, Rathmell JP, eds. *Bonica's Management of Pain*. Philadelphia: Walters Kluwer, Lippincott, Williams and Wilkins; 2010: 192.
85. Kornick CA, Santiago-Palma J, Schulman G, et al. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. *Cancer* 2003;97:3121–3124.
86. McQuay H. Opioids in pain management. *Lancet* 1999;353:2229–2232.
87. Mercadante S, Casuccio A, Agnello A, et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. *J Clin Oncol* 1998;16:3656–3661.
88. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. *J Clin Oncol* 1999;17:3307–3312.
89. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. [see comment]. *Pain* 1990;43:273–286.
90. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? [see comment]. *J Clin Oncol* 1998;16:3216–3221.
91. Klepstad P, Kaasa S, Jystad A, et al. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. *Pain* 2003;101:193–198.
92. von Gunten CF, Bruera E, Pirrello RD, et al. New opioids: expensive distractions or important additions to practice? *J Palliat Med* 2010;13: 505–511.
93. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. *J Pain Symptom Manage* 1995;10:184–186.
94. Moulin DE, Johnson NG, Murray-Parsons N, et al. Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use. *Can Med Assoc J* 1992;146:891–897.
95. Moulin DE, Kreeft JH, Murray-Parsons N, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. [see comment]. *Lancet* 1991;337:465–468.
96. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. *Clin Pharmacol Ther* 1996;59:52–61.
97. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. *Arch Intern Med* 2006;166:1280–1287.
98. Fredheim OM, Borchgrevink PC, Hegrehaes L, et al. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. *J Pain Symptom Manage* 2006;32:180–185.
99. Krantz MJ, Mehler PS. QTc prolongation: methadone's efficacy-safety paradox. *Lancet* 2006;368:556–557.
100. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. *J Clin Oncol* 2004;22:185–192.
101. Bruera E, Fainsinger R, Moore M, et al. Local toxicity with subcutaneous methadone. Experience of two centers. [see comment]. *Pain* 1991;45:141–143.
102. Morley J, Makin M. The use of methadone in cancer pain poorly responsive to other opiates. *Pain Rev* 1998;5:51–58.
103. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. *Ann Neurol* 1983;13:180–185.
104. Altman EM, Manos GH. Serotonin syndrome associated with citalopram and meperidine. *Psychosomatics* 2007;48:361–363.
105. Das PK, Warkentin DJ, Hewko R, et al. Serotonin syndrome after concomitant treatment with linezolid and meperidine. *Clin Infect Dis* 2008; 46:264–265.
106. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. *Pharmacotherapy* 2006;26: 1784–1793.
107. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. *Anesthesiology* 1993;78:36–43.
108. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). *Pain* 2001;91:123–130.
109. Darvish M, Tempero K, Kirby M, et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. *Clin Ther* 2006;28:715–724.
110. Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. *Curr Med Res Opin* 2009;25:1517–1528.
111. Houde RW. Methods for measuring clinical pain in humans. *Acta Anaesthesiol Scand Suppl* 1982;74:25–29.
112. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. *Clin Pharmacol Ther* 1988;44:335–342.
113. Portenoy RK, Moulin DE, Rogers A, et al. I.V. infusion of opioids for cancer pain: clinical review and guidelines for use. *Cancer Treat Rep* 1986;70:575–581.
114. Devulder J, Ghys L, Dhondt W, et al. Spinal analgesia in terminal care: risk versus benefit. *J Pain Symptom Manage* 1994;9:75–81.
115. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. *J Clin Oncol* 2002;20:4040–4049.
116. Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. *Neurosurgery* 1990;26:404–407.
117. Beaver W. Comparison of analgesic effects of morphine sulfate, hydroxyzine and other combinations in patients with postoperative pain. In: Bonica J, Ventafridda V, eds. *Advances in Pain Research and Therapy*. New York: Raven Press; 1976: 553.
118. Bruera E, Brenneis C, Paterson AH, et al. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. *J Pain Symptom Manage* 1989;4:3–6.
119. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. *Pain* 1992;50:75–77.
120. Goldfrank L, Weisman RS, Errick JK, et al. A dosing nomogram for continuous intravenous naloxone. *Ann Emerg Med* 1986;15:566–570.
121. Apfel CC, Cakmakaya OS, Frings G, et al. Droperidol has comparable clinical efficacy against both nausea and vomiting. *Br J Anaesth* 2009;103:359–363.
122. Thomas J, Karver S, Cooney GA, et al. Methylaltraxone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008;358:2332–2343.
123. Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. *Curr Opin Anaesthesiol* 2010;23:616–622.
124. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. *Ann N Y Acad Sci* 1981;362:161–172.
125. Gorman A, Elliott K, Inturrisi C. The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. *Neuroscience Letter* 1997;223:5.
126. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. [see comment]. *Pain* 1996;68:217–227.
127. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. *Pain* 2005;118:289–305.

128. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. *Pain* 1990;42:135-144.
129. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. *Pain* 2005;116:109-118.
130. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA* 2013;309:1359-1367.
131. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. [see comment]. *JAMA* 1998;280:1831-1836.
132. Stute P, Soukup J, Menzel M, et al. Analysis and treatment of different types of neuropathic cancer pain. *J Pain Symptom Manage* 2003;26:1123-1131.
133. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. [update of Cochrane Database Syst Rev 2000;(3):CD001133; PMID: 10908487]. *Cochrane Database Syst Rev* 2005;CD001133.
134. Wiffen PJ, McQuay HJ, Edwards JE, et al. Gabapentin for acute and chronic pain. *Cochrane Database Syst Rev* 2005;CD005452.
135. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. *Pain* 2005;115:254-263.
136. Bennett MI, Laird B, van Litsenburg C, et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. *Pain Med* 2013;14:1681-1688.
137. Deigard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. *Lancet* 1988;1:9-11.
138. Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. *Cochrane Database Syst Rev* 2005;CD003345.
139. Brose WG, Cousins MJ. Subcutaneous lidocaine for treatment of neuropathic cancer pain. *Pain* 1991;45:145-148.
140. Ehrenstrom Reiz GM, Reiz SL. EMLA—a eutectic mixture of local anaesthetics for topical anaesthesia. *Acta Anaesthesiol Scand* 1982;26:596-598.
141. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. *Pain* 1999;80:533-538.
142. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. *Cancer Treat Rep* 1985;69:751-754.
143. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. *J Clin Oncol* 1989;7:590-597.
144. Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. *Eur J Cancer* 1994;30A:22-27.
145. Abraham JL, Banffy MB, Harris MB. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life". *JAMA* 2008;299:937-946.
146. Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. [see comment]. *Arch Neurol* 1989;46:960-963.
147. Beaver WT, Wallenstein SM, Houde RW. A comparison of the analgesic effects of methotrimiprazine and morphine in patients with cancer. *Clin Pharmacol Ther* 1966;7:436-446.
148. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. *Pain* 1995;61:391-399.
149. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. [see comment]. *J Pain Symptom Manage* 2003;26:867-875.
150. Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. *J Pain Symptom Manage* 2007;33:365-371.
151. Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. *J Clin Oncol* 2012;30:3611-3617.
152. Mercadante S, Casuccio A, Genovese G. Ineffectiveness of dextromethorphan in cancer pain. *J Pain Symptom Manage* 1998;16:317-322.
153. Vranken JH, van der Vegt MH, Kal JE, et al. Treatment of neuropathic cancer pain with continuous intrathecal administration of S + ketamine. *Acta Anaesthesiol Scand* 2004;48:249-252.
154. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. *Pain* 1992;48:21-27.
155. Mouedden ME, Meert TF. Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain. *Pharmacol Biochem Behav* 2007;86:458-467.
156. Berry S, Waldron T, Winquist E, et al. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. *Can J Urol* 2006;13:3180-3188.
157. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. [see comment]. *J Clin Oncol* 1998;16:1218-1225.
158. Ernst DS, Brasher P, Hagen N, et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. *J Pain Symptom Manage* 1997;13:319-326.
159. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. [update in Cochrane Database Syst Rev. 2005;(3):CD003474; PMID: 16034900]. *Cochrane Database Syst Rev* 2002;CD003474.
160. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. *J Pain Symptom Manage* 2007;33:462-472.
161. Roth A, Kolari K. Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. *Oncology* 1986;43:283-287.
162. Warrell RP Jr, Lovett D, Dilmann FA, et al. Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. *J Clin Oncol* 1993;11:2443-2450.
163. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. *Lancet* 2011;377:813-822.
164. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132-5139.
165. Baczysk M, Czeczyski R, Milecki P, et al. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. *Nucl Med Commun* 2007;28:245-250.
166. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic review. *Radiother Oncol* 2005;75:258-270.
167. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. [see comment]. *Lancet Oncol* 2005;6:392-400.
168. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369:213-223.
169. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. *Eur J Cancer* 2012;48:678-686.
170. Keefe FJ, Abernethy AP, Campbell LC. Psychological approaches to understanding and treating disease-related pain. *Annu Rev Psychol* 2005;56:601-630.
171. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. *J Pain Symptom Manage* 2002;24:526-542.
172. Devine EC. Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer. *Oncol Nurs Forum* 2003;30:75-89.
173. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. *JAMA* 1996;276:313-318.
174. Edwards WT, Habib F, Burney RG, et al. Intravenous lidocaine in the management of various chronic pain states. *Reg Anesth* 1985;10:1-6.
175. Bruera E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. *J Pain Symptom Manage* 1992;7:138-140.
176. Waldman SD, Cronen MC. Thoracic epidural morphine in the palliation of chest wall pain secondary to relapsing polychondritis. *J Pain Symptom Manage* 1989;4:38-40.
177. Cherny NI, Arbit E, Jain S. Invasive techniques in the management of cancer pain. *Hematol Oncol Clin North Am* 1996;10:121-137.
178. Kim PS. Interventional cancer pain therapies. *Semin Oncol* 2005;32:194-199.
179. Patt R. Peripheral neurolysis and the management of cancer pain. In: Patt R, ed. *Cancer Pain*. Philadelphia: Lippincott; 1993:359.
180. Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. *Am J Gastroenterol* 2007;102:430-438.
181. Robertson DH. Transsacral neurolytic nerve block. An alternative approach to intractable perineal pain. *Br J Anaesth* 1983;55:873-875.
182. Staats PS. Neuraxial infusion for pain control: when, why, and what to do after the implant. *Oncology* 1999;13:58-62.
183. Benedetti C, Ibinson J, Adolph M. Cancer pain: anesthetic and neurosurgical approaches. In: Walsh D, Caraceni AT, Fainsinger R, et al., eds. *Palliative Medicine*. Philadelphia: Saunders Elsevier; 2009: 1394.
184. Raslan AM, Burchiel KJ. Neurosurgical advances in cancer pain management. *Curr Pain Headache Rep* 2010;14:477-482.
185. Alimi D, Rubino C, Pichard-Leandri E, et al. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. *J Clin Oncol* 2003;21:4120-4126.
186. Bardia A, Barton DL, Prokop LJ, et al. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. *J Clin Oncol* 2006;24:5457-5464.
187. Sliva JA, Marciniak C. Physical rehabilitation of the cancer patient. In: von Gunten CF, ed. *Palliative Care and Rehabilitation of Cancer Patients*. Boston: Kluwer Academic; 1998:76.